ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1623877
The Combination Treatment of Oncolytic Adenovirus H101 with Transcatheter Arterial Embolization Sequential Thermal Ablation for Hepatocellular Carcinoma: A Retrospective Study
Provisionally accepted
- Beijing Youan Hospital, Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background & Aims: Recombinant human adenovirus type 5 (H101) was demonstrated to enhance the efficacy of transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC). This study aims to analyze the efficacy and safety of oncolytic adenovirus H101 combined with TAE sequential thermal ablation in HCC. Methods: This single-center retrospective study evaluated the progression-free survival (PFS) and overall survival (OS) of HCC patients who received H101 combined with TAE sequential thermal ablation therapy from July 2015 to January 2022. Adverse reactions during treatment were recorded. Results: A total of 55 HCC patients were included, with a median follow-up of 39 months (range: 10-106 months). During the follow-up period, disease progression was observed in 43 of 55 patients, and 22 of the 55 patients died. The median OS and PFS time were 77 and 12.3 months, respectively. The one-, two-, and three-year OS rates were 94.5%, 86.3%, and 77.3%, respectively. The PFS rates at one, two and three years were 56.4%, 26.3% and 20%, respectively. Multivariate analysis revealed that the diameter was independent predictors of PFS (P = 0.023). No patient experienced a serious adverse event, or a fatal or disabling event, due to the injection of oncolytic virus. Conclusion: This study suggests that HI01 combined with TAE sequential thermal ablation is both safe and effective for HCC, warranting further investigation through prospective randomized controlled trials.
Keywords: Hepatocellular Carcinoma, oncolytic adenovirus, H101, transcatheter arterial embolization, Thermal ablation
Received: 06 May 2025; Accepted: 29 Aug 2025.
Copyright: © 2025 Jing, Zhu, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianjun Li, Beijing Youan Hospital, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.